We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Priority Review to BMS Skin Cancer Drug
FDA Grants Priority Review to BMS Skin Cancer Drug
August 18, 2010
Bristol-Myers Squibb’s (BMS) BLA for melanoma treatment ipilimumab has received a priority review designation from the FDA.